A placebo-controlled trial of Korean red ginseng extract for preventing Influenza-like illness in healthy adults

Standardized Korean red ginseng extract has become the best-selling influenza-like illness (ILI) remedy in Korea, yet much controversy regarding the efficacy of the Korean red ginseng (KRG) in reducing ILI incidence remains. The aim of the study is to assess the efficacy of the KRG extract on the ILI incidence in healthy adults.

Methods: We will conduct a randomized, double-blind, placebo-controlled study at the onset of the influenza seasons.

A total of 100 subjects 30-70 years of age will be recruited from the general populations. The subjects will be instructed to take 9 capsules per day of either the KRG extract or a placebo for a period of 3 months.

The primary outcome measure is to assess the frequency of ILI onset in participated subjects. Secondary variable measures will be included severity and duration of ILI symptoms.

The ILI symptoms will be scored by subjects using a 4-point scale.DiscussionThis study is a randomized placebo controlled trial to evaluate the efficacy of the KRG extract compared to placebo and will be provided valuable new information about the clinical and physiological effects of the KRG extract on reduction of ILI incidence including flu and upper respiratory tract infections. The study has been pragmatically designed to ensure that the study findings can be implemented into clinical practice if KRG extract can be shown to be an effective reduction strategy in ILI incidence.

Trial Registration: NCT01478009.

Author: Ki-Chan HaMin-Gul KimMi-Ra OhEun-Kyung ChoiHyang-Im BackSun-Young KimEun-Ok ParkDae-Young KwonHye-Jeong YangMin-Jeong KimHee-Joo KangJu-Hyung LeeKyung-Min ChoiSoo-Wan ChaeChang-Seop Lee
Credits/Source: BMC Complementary and Alternative Medicine

Published on: 2012-02-08

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Comments Page 0 of 0

There are currently 0 comments to display.

+ Add New Comment

Custom Search